Application of dlk1 in the diagnosis and prognosis of liver cancer

A liver cancer prognosis and application technology, applied in the field of oncology and diagnosis, can solve the lack of serum markers and other problems

Active Publication Date: 2016-01-13
SHANGHAI INST OF ONCOLOGY
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, currently there is still a lack of satisfactory serum markers for cancer (such as HCC) detection, and there is even a lack of serum markers that can be used for serum detection or liver cancer prognosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of dlk1 in the diagnosis and prognosis of liver cancer
  • Application of dlk1 in the diagnosis and prognosis of liver cancer
  • Application of dlk1 in the diagnosis and prognosis of liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0105] Serum DLK1 protein concentration was significantly elevated in patients with liver cancer

[0106] In this example, the concentration of DLK1 in the serum of 400 cases of liver cancer patients and 88 cases of healthy control group was detected by ELISA method.

[0107] The results showed that the concentration of DLK1 in HCC serum was 2378.6±337.5pg / ml (mean±SD); the concentration of DLK1 in healthy control group serum was 685.4±38.9pg / ml (mean±SD); The concentration of DLK1 was significantly higher than that of the healthy control group (P figure 2 ).

[0108] Therefore, if the concentration of DLK1 in the serum of the detected subject is ≥1000 pg / ml (more preferably ≥2000 pg / ml), it indicates that the probability of the subject suffering from liver cancer is significantly higher than that of the normal population.

Embodiment 2

[0110] The relationship between serum DLK1 concentration and various clinical indicators

[0111] In order to further explore the relationship between serum DLK1 concentration and various clinical indicators, according to the ROC curve ( image 3 ) set the cut-off value (threshold) of DLK1 as 890pg / ml, its sensitivity and specificity were 33.2% and 75.0% respectively, and the positive rate was about 22% (29 / 132). The clinicopathological indicators included in the statistical analysis mainly include patient gender, age, serum alpha-fetoprotein, hepatitis B virus surface antigen, tumor size, Edmondson histological grade, intrahepatic metastasis and associated liver cirrhosis.

[0112] Statistical analysis results showed that serum DLK1 concentration was closely related to Edmondson histological grade and tumor size in patients with liver cancer (Table 1).

[0113] Table 1. Correlation analysis between serum DLK1 concentration and clinicopathological indicators in patients with ...

Embodiment 3

[0117] Serum DLK1 concentration is closely related to survival of patients with liver cancer

[0118] In this example, the survival of DLK1-positive and DLK1-negative liver cancer patients was analyzed with 890 pg / ml as the cut-off value.

[0119] The results showed that the survival time of DLK1-negative HCC patients was significantly longer than that of DLK1-positive patients ( Figure 4 ) (P=0.033). Among them, there were 91 patients with DLK1-negative liver cancer, with a median survival time of 902 days; and 27 patients with DLK1-positive liver cancer, with a median survival period of 596 days).

[0120] The above results indicated that the serum DLK1 concentration is suitable as a serum marker for the detection and judgment of the prognosis of liver cancer.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of DLK1 in diagnosis and prognosis of a liver cancer. Specifically speaking, the invention provides application of preadipocyte factor-1 (DLK1 protein) in (a) preparation of a diagnostic reagent or kit for prognosis detection of a liver cancer and (b) preparation of a diagnostic reagent or kit for serum detection of a liver cancer. The invention also provides corresponding detection kits.

Description

technical field [0001] The present invention relates to the fields of oncology and diagnostics. More specifically, the present invention relates to the application of DLK1 in the diagnosis and prognosis of liver cancer. Background technique [0002] DLK1 (Delta-like1homologue), also known as Pref-1 (preadipocyte factor-1), is a gene first discovered and cloned in neuroblastoma (LabordaJetal, JBiolChem, 1993, 268 (6): 3817-3820 ), located on human chromosome 14q32. [0003] DLK1 protein plays a certain role in cell differentiation, especially expressed in endoderm-derived liver cells and respiratory epithelial cells. With the increase of fetal gestational age, the expression of DLK1 in normal tissues gradually decreases. [0004] The full length of the human gene Dlk1 (GeneBank accession number BC007741) is 1557bp, the open reading frame contains 1152 nucleotides, and encodes 383 amino acid residues. DLK1 protein is a transmembrane protein, including intracellular signal p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/68A61K45/00A61K48/00A61K39/395A61P35/00A61P1/16
Inventor 李锦军李红葛超
Owner SHANGHAI INST OF ONCOLOGY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap